Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI Life Science Investing
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights Life Science Investing
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results Life Science Investing
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update Life Science Investing
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Life Science Investing
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update Life Science Investing
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia Life Science Investing
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial Life Science Investing
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients Life Science Investing
